The anti-CD47 drugs market is a rapidly expanding domain. CD47 acts as a "don't eat me" signal to macrophages and plays a key role in suppressing anti-tumoral immune responses. Anti-CD47 drugs overcome this "don't eat me" signal and help macrophages recognize and engulf cancer cells. They allow the innate immune system to effectively eliminate tumor cells. Growing cancer incidence globally due to factors such as aging population, lifestyle changes, and environmental pollution is fueling demand for novel targeted therapies like anti-CD47 drugs.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.
Key players operating in the Anti CD47 Drugs Market are Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven. These companies are investing heavily in R&D to develop more effective and safer anti-CD47 drugs and gain higher market share.
The market provides major opportunities in indications like hematological and solid tumors where anti-CD47 therapies can achieve breakthroughs. Companies are conducting clinical trials across various cancer types to expand therapeutic applications.
Globally, the anti-CD47 drugs market is set to witness high growth in developing countries due to rising healthcare investments, growing cancer burden, and increased awareness. Major players are collaborating with regional companies and exploring new manufacturing and distribution partnerships to strengthen their global presence.
Market Drivers
The rising prevalence of cancer is a major driver for the anti-CD47 drugs market. According to Globocan 2020, there were around 19.3 million new cancer cases and 10.0 million cancer deaths worldwide in 2020. Furthermore, failure of existing cancer therapies to achieve long term remissions is compelling patients and healthcare providers to look for novel mechanisms like anti-CD47 drugs. The strong clinical efficacy demonstrated so far and potentially advantageous side effect profiles of these drugs also contribute to high market growth rates.
PEST Analysis
Political: Governments across various countries are aiding research on cancer treatments by providing funds. Some governments have also simplifued approval processes for anti-CD47 drugs to ensure patients have faster access.
Economic: High healthcare spending on cancer worldwide has pushed pharmaceutical companies to focus on novel drug development. Successful anti-CD47 drugs can garner blockbuster sales due to the massive patient pool of various cancers.
Social: Rising cancer incidence globally due to changing lifestyles and environmental factors is causing high patient burden on families and society. This is increasing focus on developing more effective and tolerable drugs like anti-CD47 therapeutics.
Technological: Advanced research techniques like genetic studies and targeted drug discovery have facilitated development of several anti-CD47 drug candidates. Ongoing clinical trials aim to validate their safety and efficacy for treating hard-to-cure cancers.
The anti-CD47 drug market in terms of value is concentrated majorly in North America and Europe currently. Rapidly aging populations and higher spending capabilities in these regions have accelerated clinical research and enabled pharma companies to set up manufacturing facilities locally.
Asia Pacific region is poised to emerge as the fastest growing market for anti-CD47 drugs during the forecast period. Increasing government initiatives to modernize healthcare sectors, rising incidence of cancer due to growing elderly demographics and changing lifestyles are boosting research as well as demand prospects in the developing countries of China and India specifically.
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
